Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412575 | 0.93 | LMNA (0.52) | LMNAMMP9MMP8MMP13POLB | |
| SCHEMBL9258698 | 0.91 | RARB (0.56) | LMNAMMP9MMP8MMP13POLB | |
| SCHEMBL20495545 | 0.86 | LMNA (0.73) | LMNAMMP9MMP8MMP13POLB | |
| SCHEMBL28920116 | 0.85 | MEN1 (0.47) | LMNAMMP9MMP8MMP13POLB | |
| SCHEMBL28842185 | 0.85 | LMNA (0.57) | LMNAMMP9MMP8MMP13L3MBTL1 | |
| SCHEMBL22497335 | 0.85 | LMNA (0.57) | LMNAMMP9MMP8MMP13L3MBTL1 | |
| SCHEMBL27973274 | 0.85 | LMNA (0.57) | LMNAMMP9MMP8MMP13L3MBTL1 | |
| SCHEMBL5699327 | 0.84 | ESR1 (0.44) | LMNAMMP9MMP8MMP13MAPK1 | |
| SCHEMBL2384369 | 0.84 | ESR1 (0.44) | LMNAMMP9MMP8MMP13MAPK1 | |
| SCHEMBL5699336 | 0.84 | ESR1 (0.44) | LMNAMMP9MMP8MMP13MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011109525-A1 | Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof | NOX TECHNOLOGIES, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1494658-B1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH SA (ES) | 2006-01-04 | — | — | EP | disclosed |
| EP-1494658-A1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| US-20030236202-A1 | Natural products and derivatives thereof for protection against neurodegenerative diseases | PULEVA BIOTECH, S.A. (ES) | 2003-12-25 | — | — | US | disclosed |
| WO-2003082259-A1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH, S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236202-A1 | Natural products and derivatives thereof for protection against neurodegenerative diseases | SNCA, HTT, PARK7 | LMNA 543/4885MMP9 672/4885MMP8 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.